CN219579137U - Corrosion-resistant prostate functional urethral stent - Google Patents

Abstract

The utility model discloses a corrosion-resistant prostate functional urethral stent, which comprises a supporting frame body and a corrosion-resistant layer, wherein the supporting frame body is provided with a first opening, a second opening and a communication channel which is communicated with the first opening and the second opening, and the corrosion-resistant layer is arranged on the inner wall of the supporting frame body which forms the communication channel.

Description

Corrosion-resistant prostate functional urethral stent

Technical Field

The utility model relates to the field of medical appliances, in particular to a corrosion-resistant prostate functional urethral stent.

Background

Prostate diseases are common in many areas of the world, especially in China, where men, after entering a certain age group, may have a tendency to fibrosis and be accompanied by an increase in volume. The enlarged volume of the prostate will press the patient's urethra, thereby reducing the cross-sectional diameter of the patient's pressed urethra and preventing the patient from urinating normally.

After enlargement of the prostate of a patient, there are generally two methods for medical solutions in order to ensure that the patient can urinate normally, one of them being: surgical excision of the enlarged prostate; and secondly, the urethra of the patient is strutted through the urethra support so that the urethra of the patient can have a cross-sectional diameter of a preset size.

The enlarged prostate gland of surgical excision is gradually abandoned because of irreversible physiological effects on the patient, such as loss of sexual function. While the urinary tract of a patient can be ensured to be urinated by the way of expanding the urinary tract of the patient through the urinary tract stent, the urine in the urinary bladder of the patient can directly flow out due to the fact that the traditional urinary tract stent cannot be contracted after being implanted into the urinary tract of the patient. Therefore, the subsequently improved urethral support is generally provided with a structure capable of preventing urine from flowing out, and when a patient needs to drain, the patient can drain urine only by manually opening the structure capable of preventing urine from flowing out.

A prostatic urethra stent system capable of autonomous urination disclosed in CN207821957U and a prostatic urethra stent used by the same, and a prostatic stent capable of autonomous urination disclosed in CN 211750302U.

While the urethral stents disclosed in the prior art are capable of allowing a user to patient and preventing urination, the urethral stents of the prior art do not allow the patient to retain the physiological urination response of the human body. It is well known that the nervous system of the human body controls the physiological response of the human body, as does the physiological urination response of the human body. While the nervous system of the human body follows the principle of feeding and discharging, that is, when the human body has the intention of urination, the human body urinates, and if the human body urinates directly without awareness of urination, the nervous reflex system of the human body controlling urination will deteriorate, even be lost, over time.

In the prior art, most of urination brackets are compulsory urination, namely, if a structure for preventing urine from flowing out is opened, no matter whether a patient has urination consciousness or not, the urination will be performed, so that the normal physiological urination reaction of the human body can be destroyed.

In addition, in order to ensure a stable supporting effect of the urethral stent, the urethral stent is generally made of a metal material in the prior art. The urethra is an important channel for discharging liquid in the human body, so that the pH value of the liquid discharged through the urethra is greatly influenced by eating habits of the human body. In other words, sometimes, the liquid discharged from the human urethra has high acidity, and sometimes, the liquid discharged from the human urethra has high alkalinity, and when the metal stent exists in the urethra with relatively complex pH value for a long time, the structure and plasticity of the metal stent are affected, so that the service life of the metal stent is necessarily reduced, and the stability of the metal stent for expanding the urethra is affected.

In addition, the existing urethral stent needs to remain in the urethra of the human body for a long period of time after being implanted into the human body to prop open the inner wall of the urethra. In other words, the existing urethral stents are required to closely fit the inner wall of the human urethra. The urethral cells of the human body are stimulated to be easy to proliferate after being pressed, so that after the stent is implanted into the urethra of the human body for a preset time, new cells are proliferated at the contact part of the urethral stent and the inner wall of the urethra, and the stimulated cells are eliminated.

However, after a certain period of use, the stent needs to be removed from the urethra of the human body for replacement or maintenance, and once the stent is wrapped by cells on the inner wall of the urethra, the removal of the stent is plagued.

Disclosure of Invention

Another advantage of the present utility model is to provide a corrosion resistant prostate functional urinary tract stent that can accommodate more complex ph urine environments and maintain good stability of the stented urethra.

Another advantage of the present utility model is to provide a corrosion resistant prostate functional urinary tract stent that is capable of responding to changes in the user's urination response and that is better suited for use by the user.

Another advantage of the present utility model is to provide a corrosion resistant prostate functional urinary tract stent that can effectively delay proliferation of new cells at the location where the urinary tract stent contacts the inner wall of the urinary tract, thereby facilitating post-maintenance.

Another advantage of the present utility model is to provide a corrosion resistant prostate functional urinary tract stent that can greatly reduce the foreign body sensation of the user.

Another advantage of the present utility model is to provide a corrosion-resistant prostate functional urinary tract stent, which can rapidly respond to urination and urination of a user and rapidly block the user's urethra from the outside after urination is completed, thereby effectively preventing urinary tract infection of the user.

To achieve at least one of the above advantages, one advantage of the present utility model is to provide a corrosion resistant prostate functional urinary tract stent comprising:

the support frame body is provided with a first opening, a second opening and a communication channel for communicating the first opening and the second opening;

and the corrosion-resistant layer is arranged on the inner wall of the support frame body forming the communication channel.

According to an embodiment of the utility model, the corrosion resistant prostate functional urinary tract stent comprises a drug coating, wherein the drug coating is disposed on an outer wall of the supporting stent body.

According to an embodiment of the present utility model, the outer wall of the supporting frame body has at least one embedding groove, wherein the embedding groove is embedded with a drug for delaying the excessive proliferation of the endothelial cells of the urethra.

According to an embodiment of the present utility model, the drug for delaying the excessive proliferation of endothelial cells of urinary tract comprises one of paclitaxel/rapamycin-anticancer drugs.

According to an embodiment of the present utility model, the interval between the drug for delaying the excessive proliferation of endothelial cells of urethra, such as paclitaxel/rapamycin-anticancer drug, and the urethra of the user is at least not smaller than the interval between the outer wall of the supporting frame body and the urethra of the user.

According to one embodiment of the present utility model, the corrosion-resistant prostate functional urethral stent comprises at least one biological shutter that is disposed in the communication channel in a manner that enables communication between the first opening and the second opening when subjected to a predetermined magnitude of fluid pressure, and blocks the first opening and the second opening when subjected to a magnitude of fluid pressure that is lower than the predetermined magnitude.

According to one embodiment of the utility model, the outer edge of the biological opening and closing device is arranged on the end edge of the first opening formed on the supporting frame body, and the biological opening and closing device is arranged on the end edge of the first opening formed on the supporting frame body, so that at least one communication opening capable of being opened and closed can be formed in the middle of the biological opening and closing device when the biological opening and closing device is subjected to the fluid pressure with the preset magnitude.

According to one embodiment of the utility model, the predetermined magnitude of fluid pressure is set to 300 milliliters, 5 centimeters of water, 10 millimeter diameter evacuated tubes, 3 pounds of force.

According to an embodiment of the utility model, the bio-opener comprises at least 3-valve polymer telescopic membranes, wherein each membrane is provided with an edge part, two side shoulder parts and a through stopping part opposite to the edge parts, wherein at least 3-valve polymer telescopic membranes are arranged on the first opening side by side, the edge part of each membrane is fixed on the support frame body, the side shoulder parts of two adjacent membranes are mutually fixed, and the through stopping parts of all the membranes form the communication opening in a surrounding mode capable of opening and closing.

According to an embodiment of the present utility model, the bioswitch includes 4-flap or 5-flap polymeric stretchable membranes, each of the membranes is held in the communicating channel obliquely, the extending direction of the support frame body is set to be an axial direction when the bioswitch holds the communicating port closed, wherein an angle of each of the membranes to the axial direction is set to 15 ° to 20 °, each of the edge portions of the membranes has a head portion and a tail portion, wherein a cross section of the edge portion gradually decreases from the head portion toward the tail portion when the bioswitch is in an open state in which the communicating port is formed, and the head portion of an edge portion of one of the adjacent two membranes corresponds to the tail portion of the edge portion of the other membrane, and the tail portion of the edge portion of the adjacent two membranes contracts to be fused into the edge portion of the other membrane from the head portion of the other membrane when the bioswitch is in a closed state, and the tail portion of the adjacent two membranes is in an open state from the head portion of the other membrane.

Drawings

Fig. 1 shows a perspective view of the corrosion resistant prostate functional urethral stent of a first embodiment of the utility model.

Fig. 2 shows a schematic view of the corrosion-resistant prostate functional urethral stent of the first embodiment of the utility model in the opened state of the bioswitch.

Fig. 3 shows a schematic view of the corrosion resistant prostate functional urethral stent of the first embodiment of the utility model in a closed state.

Fig. 4 shows a schematic view of the corrosion resistant prostate functional urethral stent of the first embodiment of the utility model at an angle.

Fig. 5 shows an enlarged schematic view of the structure of the part of the corrosion resistant prostate functional urethral stent according to the first embodiment of the utility model.

Fig. 6 is an enlarged view showing another part of the construction of the corrosion resistant prostate functional urethral stent according to the first embodiment of the utility model.

Fig. 7 shows a schematic view of the corrosion resistant prostate functional urethral stent of the first embodiment of the utility model in one scenario.

Fig. 8 shows a schematic view of the corrosion resistant prostate functional urethral stent of the first embodiment of the utility model in another scenario.

Fig. 9 shows a perspective view of the corrosion resistant prostate functional urethral stent of a second embodiment of the utility model.

Fig. 10 shows a perspective view of the corrosion resistant prostate functional urethral stent of a third embodiment of the utility model.

Detailed Description

The following description is presented to enable one of ordinary skill in the art to make and use the utility model. The preferred embodiments in the following description are by way of example only and other obvious variations will occur to those skilled in the art. The basic principles of the utility model defined in the following description may be applied to other embodiments, variations, modifications, equivalents, and other technical solutions without departing from the spirit and scope of the utility model.

It will be appreciated by those skilled in the art that in the present disclosure, the terms "longitudinal," "transverse," "upper," "lower," "front," "rear," "left," "right," "vertical," "horizontal," "top," "bottom," "inner," "outer," etc. refer to an orientation or positional relationship based on that shown in the drawings, which is merely for convenience of description and to simplify the description, and do not indicate or imply that the apparatus or elements referred to must have a particular orientation, be constructed and operated in a particular orientation, and therefore the above terms should not be construed as limiting the present utility model.

It will be understood that the terms "a" and "an" should be interpreted as referring to "at least one" or "one or more," i.e., in one embodiment, the number of elements may be one, while in another embodiment, the number of elements may be plural, and the term "a" should not be interpreted as limiting the number.

Referring to fig. 1 to 8, a corrosion-resistant prostate functional urethral stent according to a preferred embodiment of the present utility model, which can be used to prop open the urethra of a patient and can maintain physiological urination response of the human body, will be described in detail below.

In one embodiment, the corrosion resistant prostate functional urinary tract stent includes a support frame 10 and at least one bio-switch 20. The supporting frame 10 has a first opening 101, a second opening 102, and a communication channel 103 for communicating the first opening 101 and the second opening 102, wherein at least one bio-switch 20 is disposed in the communication channel 103 to close or open the first opening 101 and the second opening 102. As an example, one of the bioswitches 20 is provided to the first opening 101 of the communication channel 103.

As will be appreciated by those skilled in the art, in one embodiment, one of the bioswitches 20 is disposed in the second opening 102. In yet another embodiment, the first opening 101 and the second opening 102 may be provided with one of the bioswitches 20, respectively. In other embodiments, the bio-switch 20 may be disposed at other locations than the first and second openings 101 and 102.

To enable those skilled in the art to understand the embodiments of the present utility model, at least one embodiment of the present utility model will be described with reference to the bio-switch 20 being disposed in the first opening 101, wherein the first opening 101 is close to and faces the bladder of the user after the corrosion-resistant prostate functional urethral stent is placed in the urethra of the human body.

The bioswitch 20 is provided in the communication passage 103 so as to be capable of communicating the first opening 101 and the second opening 102 when subjected to a predetermined magnitude of fluid pressure, and blocking the first opening 101 and the second opening 102 when subjected to a magnitude of fluid pressure lower than the predetermined magnitude.

In particular, in one embodiment, the outer edge of the bioswitch 20 is mounted on the support body 10 forming an end edge of the first opening 101. The bio-switch 20 is provided so that at least one communication port 201 is formed in the middle portion to be openable and closable when a predetermined amount of fluid pressure is applied thereto.

Thus, after the corrosion-resistant prostate functional urinary meatus stent is implanted in the patient's urinary meatus, when the communication port 201 is formed at the middle portion of the bio-switch 20, the user's urinary meatus can communicate with the communication channel 103 of the supporting frame body 10 through the communication port 201, thereby allowing the user to urinate. In particular, in the process that the urine of the user gradually remains and accumulates in the bladder of the user, the fluid pressure formed by the urine of the user gradually increases, and when the fluid pressure formed by the urine of the user is greater than the maximum pressure that the bio-switch 20 can be kept to close the communication port 201, the communication port 201 is opened, so that the urine of the user bladder can be discharged from the user's urethra through the communication port 201, the communication channel 103 of the support frame 10 and the second opening 102 in sequence.

When the urine of the user gradually remains and accumulates in the bladder of the user and the fluid pressure of the accumulated urine is smaller than the maximum pressure that the bio-switch 20 can receive to keep the communication port 201 closed, most parts of the urethra, bladder, etc. of the user are isolated from the outside by the bio-switch 20 because the communication port 201 is closed. Thus, external bacteria, dust, viruses and other dirt can be effectively prevented from entering the urethra of the user, and the urethra of the user can be effectively prevented from being disturbed.

Preferably, the predetermined magnitude of fluid pressure is set to 300 milliliters, 5 centimeters of water, 10 millimeter diameter evacuated tubes, 3 pounds of force. Experiments have shown that most people produce urine by conscious urination at pressures in the urethra that are close to: 300 ml, 5 cm water column, 10 mm diameter evacuated tube, 3 lbs. force. Thus, when the user intentionally urinates, the pressure of the fluid in the bladder is controlled, and when the pressure of the fluid in the user's bladder is greater than the predetermined magnitude of the fluid pressure, the bio-switch 20 may automatically form the communication port 201. And when the user disappears, the bio-switch 20 may automatically close the communication port 201.

It is worth mentioning that in one embodiment, the communication port 201 is implemented as a macroscopic opening; in a variant embodiment, however, the communication port 201 may be embodied as an invisible opening allowing the passage of the fluid, i.e. a channel similar to the permeable membrane permeable to the fluid. In order for those skilled in the art to understand the present utility model, at least one embodiment of the present utility model is described only by taking an example in which the communication port 201 is implemented as a macroscopic opening, and those skilled in the art will understand that this is not limiting to the present utility model.

As will be appreciated by those skilled in the art, since the human body can consciously control the pressure of the fluid in the own bladder, even if the original pressure of the fluid in the user's bladder is greater than the predetermined magnitude of the fluid pressure, the pressure of the fluid in the user's bladder finally given to the bio-switch 20 is less than the predetermined magnitude of the fluid pressure due to the subconscious control of the user, the bio-switch 20 is still in the closed state, i.e., the communication port 201 is closed.

It can be further understood by those skilled in the art that, unlike the prior art, since the opening and closing of the bio-switch 20 is the engagement and control of the urination consciousness of the user, the corrosion-resistant prostate functional urethral stent provided with the bio-switch 20 can continuously train the urination consciousness of the user when being used by the user, so that the corrosion-resistant prostate functional urethral stent can not only control the on-off of the user's urethra and bladder, but also maintain the normal urination consciousness of the user. In the prior art, as in the technical schemes disclosed in CN207821957U or CN211750302U, the on-off of the urethra and the bladder of the user are controlled manually by the user, and the user's urination consciousness is not needed or not involved and controlled, and in long term, the urination consciousness of the user is lost, thus causing other problems.

In one example, the bio-switch 20 is implemented as a flexible elastic membrane.

Preferably, the bio-switch 20 comprises at least 3-flap polymeric flexible membranes 21, wherein each membrane 21 has an edge portion 211, two side shoulder portions 212 and a stop portion 213 opposite to the edge portion 211, wherein at least 3-flap polymeric flexible membranes 21 are arranged side by side at the first opening 101, wherein the edge portion 211 of each membrane 21 is fixed on the support frame body 10. Furthermore, the side shoulders 212 of two adjacent diaphragms 21 are fixed to each other. The communication ports 201 are formed so as to be openable and closable around the stopper portions 213 of all the diaphragms 21.

Referring to fig. 1 and 9 and fig. 10, in one embodiment, the bio-breaker 20 includes at least 3 flaps of the polymeric telescoping membrane 21. In one embodiment, the bio-switch 20 includes at least 4 flaps of the polymeric telescoping membrane 21. In yet another embodiment, the bio-switch 20 includes at least 5 flaps of the polymeric telescoping membrane 21. That is, the bioswitch 20 includes at least 3 petals. In order to enable those skilled in the art to understand the present utility model, at least one embodiment of the present utility model is described by taking the bio-switch 20 including the 5-piece polymeric flexible membrane 21 as an example, but this is not a limitation of the present utility model.

It should be noted that, when the bio-switch 20 is in the closed state, the side shoulder 212 and the through-stop 213 of each membrane 21 contact each other to close the communication port 201. And when the bio-switch 20 is in an open state, i.e., the bio-switch 20 is formed with the communication port 201, the communication port 201 is opened, and at this time, the diaphragm 21 receives a pressure greater than the predetermined magnitude of fluid pressure. It should be noted that, since the diaphragm 21 has stretchability, the larger the pressure applied to the diaphragm 21, the larger the size of the communication port 201 is formed, and thus, the user can be made to urinate promptly, which can also respond to the awareness of urination of the user. That is, as the user's awareness of urination becomes stronger, the pressure corresponding to the impact of the diaphragm 21 is greater, and accordingly, the size of the communication port 201 opened is greater, thereby enabling the user to urinate faster. Conversely, when the user's awareness of urination is weaker, the pressure corresponding to the impact of the diaphragm 21 is smaller, and accordingly, the size of the communication port 201 opened is larger, thereby enabling the user to urinate slowly.

That is, by providing the bio-switch 20 as the polymer flexible membrane 21 of at least three flaps, not only is it advantageous for the exercise of the user's awareness of urination, but also it is possible to respond to the change of the user's awareness of urination.

Preferably, the polymer flexible membrane 21 is made of titanium alloy, pyrolytic carbon fiber film, or the like.

Also preferably, each of the diaphragm 21 is held obliquely at the first opening 101, and the stopper 213 of the diaphragm 21 in the state of being held obliquely is located closer to the second opening 102, that is, each of the diaphragm 21 is inclined so as to extend into the communication passage 103 formed in the support body 10.

Preferably, when the bio-switch 20 keeps the communication port 201 closed, the extending direction of the support body 10 is taken as an axial direction, wherein an angle θ between each of the diaphragms 21 and the axial direction is set to 15 ° to 20 °, preferably 18 °.

By in vitro experimental conditions: 300 ml, 5 cm water column, 10 mm diameter evacuated tube. The basal force surface for bladder contraction upon pressurization with 3 pounds of external force, i.e., physiological urination:

(1) When the angle between each diaphragm 21 and the axial direction is set to 90 °,3 pounds of external force is applied, and 5 cm of water column cannot form the communication port 201. Only a drip-like drip is formed.

(2) When the included angle between each piece of membrane 21 and the axial direction is set to be 10 degrees, 3 pounds of external force is applied, the 5 cm water column closer can open to the far end of the urethra for about 30 degrees, the 300 milliliter water volume is emptied for about 4-5 minutes, and the communication port 201 is closed rapidly for about 3-4 seconds.

(3) When the included angle between each piece of membrane 21 and the axial direction is set to be 20 degrees, 3 pounds of external force is applied, the 5 cm water column closer can open to the far end of the urethra for about 60 degrees, the 300 milliliter water volume emptying time is about 65-75 seconds, and the communication port 201 is closed rapidly for about 5-6 seconds.

(4) When the included angle between each piece of membrane 21 and the axial direction is set to be 30 degrees, 3 pounds of external force is applied, the 5 cm water column closer can open to the far end of the urethra for about 75 degrees, the 300 milliliter water volume emptying time is about 55-60 seconds, the communication port 201 is closed slowly, and the time is about 15-16 seconds. There is a risk of retrograde urinary tract infection.

That is, when the angle between each of the diaphragms 21 and the axial direction is set to 15 ° to 20 °, not only the time for urination by the user but also the rapid closure of the communication port 201 can be ensured.

Further, the edge portion 211 of each of the diaphragms 21 has a head portion 2111 and a tail portion 2112, wherein when the bioswitch 20 is in the open state forming the communication port 201, the cross-sectional diameter of the edge portion 211 gradually decreases from the head portion 2111 toward the tail portion 2112, and the head portion 211 of the edge portion 211 of one of the adjacent two diaphragms 21 corresponds to the tail portion 212 of the edge portion 211 of the other diaphragm 21.

It should be noted that, by such an arrangement, the contact area between the outer wall of the bio-switch 20 and the urethra of the user can be reduced, thereby reducing the foreign body sensation of the user. In addition, since each of the diaphragms 21 has stretchability, and the cross-sectional diameter of the rim portion 211 is gradually reduced from the head portion 2111 to the tail portion 2112 when the bio-switch 20 is in the opened state in which the communication port 201 is formed, it is possible to increase the speed in which the communication port 201 is formed and the communication port 201 is closed, thereby enabling a user to urinate more quickly and isolate the user's urethra after urination is completed more quickly.

Preferably, when the bioswitch 20 is in the closed state, the tail portion 2112 of the edge portion 211 of one of the adjacent two membranes 21 contracts to merge from the head portion 2111 of the edge portion 211 of the other membrane 21 into the edge portion 211 of the other membrane 21. While the bio-switch 20 is in the open state, the tail portion 2112 of the edge portion 211 of the adjacent two of the membranes 21 is moved out of the head portion 2111 of the edge portion 211 of the other membrane 21.

It will be appreciated that such a design is effective to increase the speed of forming the communication port 201 and closing the communication port 201.

Preferably, the support body 10 is embodied in a memory alloy, preferably NiTi memory alloy.

It will be appreciated by those skilled in the art that NiTi memory alloys have excellent biocompatibility and corrosion resistance, while having exceptional memory properties and superelasticity. The inner support is in a softened state under the temperature of 0-10 ℃, namely, the shape of the inner support under the ice water can be changed within a certain range, the corrosion-resistant prostate functional urethral support is delivered into a narrow area of the user's body urethra through an imbedding device, the corrosion-resistant prostate functional urethral support can be immediately restored to the original shape under the body temperature, and the generated radial expansion tension acts on the inner wall of the urethra, so that the narrow is expanded.

Preferably, the support frame 10 is provided in a cylindrical shape, more preferably in a cylindrical shape. More preferably, the supporting body 10 is implemented in a mesh structure, so that a contact area between the supporting body 10 and the urethra of the user can be effectively reduced, thereby greatly reducing the foreign body sensation of the user. In addition, the supporting body 10 provided in the mesh structure also has better shape recovery performance, and particularly when the supporting body 10 is implemented to be made of a memory alloy, the supporting body 10 of the mesh structure can be quickly recovered to a shape expanding the urethra of the user.

Preferably, the outer wall of the supporting frame body 10 is provided with a drug coating 30, wherein the drug coating 30 is formed of a drug for delaying the excessive proliferation of endothelial cells of urinary tract, such as embedded paclitaxel/rapamycin-anticancer drugs.

It is worth mentioning that the corrosion-resistant prostate functional urethral stent needs to remain on the urethra of the human body for a long period of time for expanding the inner wall of the user's urethra after being implanted in the human body. In other words, the supporting body 10 of the corrosion-resistant prostate functional urethral stent is required to closely fit to the inner wall of the urethra of the human body. The urethral cells of the human body are stimulated to be easy to proliferate after being pressed, so that after the corrosion-resistant prostate functional urethral stent is implanted into the urethra of the human body for a preset time, new cells are likely to proliferate at the contact part of the urethral stent and the inner wall of the urethra, thereby eliminating the stimulation.

And because the outer wall of the supporting frame body 10 is provided with the drug coating 30, the overgrowth of the endothelial cells of the urethra can be effectively delayed, and the service cycle of the corrosion-resistant prostate functional urethral stent can be prolonged.

Preferably, the outer wall of the supporting frame body 10 has at least one embedding groove 104, wherein the embedding groove 104 is embedded with a drug for delaying the overgrowth of endothelial cells of urethra, such as paclitaxel/rapamycin-anticancer drug. Preferably, after embedding, the interval between the drug for delaying the excessive proliferation of endothelial cells of urethra, such as paclitaxel/rapamycin-anticancer drug, and the urethra of the user is at least not smaller than the interval between the outer wall of the supporting frame body 10 and the urethra of the user, so that it is ensured that the drug embedded in the embedding groove 104 can directly contact with the urethral cells of the user after the supporting frame body 10 is implanted into the urethra of the user.

In one embodiment, the inner wall of the support body 10 is provided with a corrosion resistant layer 40. Preferably, the corrosion-resistant layer 40 is formed of a polymer film resistant to acid and alkali corrosion.

As can be appreciated by those skilled in the art, since the urethra is an important channel for the human body to drain fluid from the body, the ph of the fluid drained by the urethra is greatly affected by the eating habits of the human body. In other words, sometimes the liquid discharged from the human urethra is more acidic, and sometimes the liquid discharged from the human urethra is more basic. The existing urethral stent needs to prop open the urethra of the human body and needs to have larger plasticity, so that the existing urethral stent mostly adopts a metal stent, and when the metal stent exists in the urethra with relatively complex pH value for a long time, the structure and the plasticity of the metal stent are affected, and thus, the service life of the metal stent is necessarily reduced.

And after the inner wall of the supporting frame body 10 is provided with the corrosion-resistant layer 40, the corrosion of urine to the supporting frame body 10 can be effectively delayed or even prevented, so that the supporting frame body 10 has a longer service life.

It will be appreciated by persons skilled in the art that the embodiments of the utility model described above and shown in the drawings are by way of example only and are not limiting. The advantages of the present utility model have been fully and effectively realized. The functional and structural principles of the present utility model have been shown and described in the examples and embodiments of the utility model may be modified or practiced without departing from the principles described.

Claims (10)

1. A corrosion resistant prostate functional urinary tract stent, characterized in that the corrosion resistant prostate functional urinary tract stent comprises:

the support frame body is provided with a first opening, a second opening and a communication channel for communicating the first opening and the second opening;

and the corrosion-resistant layer is arranged on the inner wall of the support frame body forming the communication channel.

2. The corrosion resistant prostate functional urinary tract stent of claim 1, comprising a drug coating, wherein the drug coating is disposed on an outer wall of the support body.

3. The corrosion resistant prostate functional urinary tract stent of claim 2 wherein the outer wall of the support body has at least one embedding groove wherein the embedding groove is embedded with a drug that delays the hyperproliferation of urinary tract endothelial cells.

4. A corrosion resistant prostate functional urinary tract stent according to claim 3, wherein said drug for delaying the hyperproliferation of urinary tract endothelial cells comprises one of paclitaxel/rapamycin-anticancer drugs.

5. The corrosion resistant prostate functional urinary tract stent of claim 4 wherein the spacing between the drug embedded with the paclitaxel/rapamycin-anticancer drug that delays the hyperproliferation of urinary tract endothelial cells and the user's urethra is at least not less than the spacing between the outer wall of the supporting stent body and the user's urethra.

6. The corrosion resistant prostate functional urinary tract stent of claim 1, comprising at least one biological shutter disposed in the communication channel in a manner that enables communication between the first opening and the second opening when subjected to a predetermined magnitude of fluid pressure and blocks the first opening and the second opening when subjected to a magnitude of fluid pressure below the predetermined magnitude.

7. The corrosion resistant prostate functional urinary tract stent of claim 6 wherein said bioswitch outer rim is mounted to said support body forming an end rim of said first opening, said bioswitch being configured to form at least one communication port in the middle that is openable and closable when subjected to a predetermined magnitude of fluid pressure.

8. The corrosion resistant prostate functional urethral stent of claim 6 or 7, wherein said predetermined magnitude of fluid pressure is set to 300 milliliters, 5 centimeters of water, 10 millimeter diameter evacuation tubes, 3 pounds of force.

9. The corrosion resistant prostate functional urinary tract stent of claim 7 wherein said bioswitch comprises at least 3 flaps of polymeric telescoping membranes, wherein each of said membranes has an edge portion, two side shoulders and a stop portion opposite said edge portion, wherein at least 3 flaps of said polymeric telescoping membranes are disposed side-by-side in said first opening, wherein said edge portion of each of said membranes is secured to said support frame, side shoulders of adjacent two of said membranes are secured to each other, and said stop portions of all of said membranes are circumscribing said communication opening to form an openable and closable.

10. The corrosion resistant prostate functional urethral stent according to claim 9, wherein said bioswitch comprises 4-or 5-flap polymeric telescoping membranes, each of said membranes being held obliquely in a communication channel, with an extending direction of said support frame body being axial when said bioswitch holds said communication port closed, wherein an angle of each of said membranes with said axial direction is set to 15 ° to 20 °, said edge portion of each of said membranes having a head portion and a tail portion, wherein a cross-section of said edge portion gradually decreases from said head portion to said tail portion when said bioswitch is in an open state forming said communication port, and said head portion of an edge portion of an adjacent one of said membranes corresponds to said tail portion of said edge portion of another membrane, and said tail portion of said edge portion of said adjacent two of said membranes contracts from said tail portion of said edge portion of said other membrane when said bioswitch is in a closed state, and said tail portion of said edge portion of said membrane is in a closed state when said bioswitch is in said open state from said head portion of said edge portion of said other membrane.